Clinical trials
Pelvic Organ Prolapse trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
105 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 10 |
| 2020 | 10 |
| 2021 | 10 |
| 2022 | 6 |
| 2023 | 9 |
| 2024 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 105 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking Union Medical College Hospital | 9 |
| National Taiwan University Hospital | 4 |
| Assiut University | 3 |
| Medical University of Vienna | 3 |
| Peking University People's Hospital | 3 |
| Saint Petersburg State University, Russia | 3 |
| Charles University, Czech Republic | 2 |
| HaEmek Medical Center, Israel | 2 |
| IRCCS San Raffaele | 2 |
| Kaiser Permanente | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pelvic Organ Prolapse | 105 |
| Uterine Prolapse | 8 |
| Urinary Incontinence, Stress | 7 |
| Urinary Incontinence | 6 |
| Cystocele | 5 |
| Rectocele | 4 |
| Prolapse | 3 |
| Urinary Bladder, Overactive | 3 |
| Hernia | 2 |
| Pelvic Floor Disorders | 2 |
Trials
Showing 51 to 75 of 105. Each trial links to its page on Pharma Observatory.
5 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.